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Abstract
Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in
children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of
these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in
young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the
developmental phase targeting active and passive immunization.
Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was
done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV
relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts
(leading basic scientists, international public health researchers, international policy makers and representatives of
pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the
condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered
questions from the CHNRI framework and their “collective optimism” towards each criterion was documented on a
scale from 0 to 100%.
Results: In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed
very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of
optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to
end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health
workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of
optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism
for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding
acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using
monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism
regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels
of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers;
and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a
high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a
maximum of about 10%.
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any medium, provided the original work is properly cited.Conclusion: Although monoclonal antibodies have proven to be effective in providing protection to high-risk
infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate
vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine
against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a
high impact on morbidity and mortality due to severe ALRI.
Background
Respiratory Syncytial Virus (RSV) is the commonest
cause of acute lower respiratory tract infections (ALRI),
here defined as pneumonia and bronchiolitis, in children
under the age of 5 years (22% of all ALRI episodes) and is
estimated to be responsible for about 53,000 to 199,000
deaths annually [1]. A majority of the episodes of RSV-
associated ALRI in young children occur in the first year
of life. Stang estimated that the annual economic burden
due to RSV-LRI hospitalisation in the United States alone
is $43.2 to $69.1 million for all children aged less than 5
years and $36.5 to $58.5 million in the case of infants [2].
RSV is thought to account for approximately 85% of
cases of bronchiolitis and approximately 20% of cases of
childhood pneumonia [3]. Though in most cases the
infection resolves without any sequelae, in some cases it
can impact on the future health state of the child. Several
studies have demonstrated an association between RSV
infection in the first two years of life and the subsequent
development of wheezing and LRI hospitalisations in the
first decade of life [4-7]
Presently, there is no effective vaccine to combat this
significant disease burden. Several candidate vaccines as
well as immunoprophylaxis which hold promise are
under various stages of development. We aimed to
review the existing literature, outlining the progress of
the emerging vaccines and immunoprophylaxis against
RSV at all stages of development; present the evidence
regarding key issues surrounding these products and
assess the level of collective optimism of international
experts over its priority status for receiving investment
support. The paper is presented as part of a series of
papers, each in turn focusing on different emerging vac-
cines and other interventions against pneumonia.
Methods
We used a modified Child Health and Nutrition
Research Initiative (CHNRI) methodology for setting
priorities in health research investments. The methodol-
ogy has been described in great detail [8-12] and imple-
mented in a variety of settings [13-18].
CHNRI exercise – stage I: identification and selection of
studies
We conducted a systematic literature review using the
following criteria: answerability, cost of development,
cost of product, cost of implementation, efficacy and
effectiveness, deliverability, affordability, sustainability,
maximum potential impact on disease burden reduction,
acceptability to health workers, acceptability to end
users and equity [15] (Figure 1). The following search
terms: respiratory syncytial virus, vaccination, immuni-
zation, infants, and children were used. Specific terms
were used for active and maternal immunization and for
the specific criteria using MeSH headings and trunca-
tion (Supplementary table S1 in additional file 1). The
search was limited to Ovid MEDLINE, Embase, Global
Health, Web of Science, LILACS, IndMed, and grey lit-
erature (SIGLE) databases from January 1994 to July
2009 (updated in August 2010). This was supplemented
with hand searching of online journals and scanning of
reference lists of identified citations. A total of 3138
articles were identified initially of which 70 articles were
found suitable for full-text review. The inclusion and
exclusion criteria are outlined in Table 1.
CHNRI exercise – stage II: an expert opinion exercise
We shared the initial review of the literature with 20
experts. The list of chosen experts included five leading
basic scientists, five international public health research-
ers, five international policy makers and five representa-
tives of the pharmaceutical companies. The 20 experts
were chosen based on their excellent track record in
child health research (but were not specifically involved
with RSV disease research). We initially offered partici-
pation to the 20 experts with the greatest impact of
publications in their area of expertise over the past 5
years (for basic researchers and international public
health researchers), or for being affiliated to the largest
pharmaceutical company in terms of vaccination pro-
gramme or international agency in terms of their annual
budget. For those who declined to participate (4 experts
- about 20% - mainly due to conflicting arrangements/
travel), replacements were found using the same criteria:
for basic scientists and public health researchers we
used Web of Knowledge and “ALRI” as search subject
and limited time period to 2001-2008. This gave us a
larger number of papers, which we sorted according to
number of citations received. Then, we went down the
ranks and invited the corresponding authors of the stu-
dies that were most relevant to the topic of our expert
panel. The policy makers and industry representatives
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Page 2 of 16accepted our invitation on the condition of anonymity,
due to sensitive nature of their involvement in such
exercises. About half of the experts were either affiliated
to institutions in developing countries or had previous
experience of working in developing country settings.
The experts met during September 7-13, 2009 in
Dubrovnik, Croatia, to conduct the 2nd stage of CHNRI
expert opinion exercise. The process of second-stage
CHNRI is shown in Figure 2. All invited experts dis-
cussed the evidence provided in CHNRI stage I, and
then answered questions from CHNRI framework (Sup-
plementary table S2 in additional file 1). Their answers
Figure 1 A summary of Stage I of the CHNRI process of evaluation of an emerging intervention (a systematic review of the key CHNRI
criteria). CHNRI- Child Health and Nutrition Research Initiative.
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“N e i t h e rY e sn o rN o ” (0.5 points) or “Don’tk n o w ”
(blank). Their “collective optimism” towards each criter-
ion was documented on a scale from 0 to 100%. The
interpretation of this metric for each criterion is
straightforward: it is calculated as the number of points
that each evaluated type of emerging RSV vaccine
received from 20 experts (based on their responses to
questions from CHNRI framework), divided by the max-
imum possible number of points (if all answers from all
experts are “Yes“) [8-12].
Results
We identified 70 articles andp r o d u c tm o n o g r a p h sf o r
inclusion. Currently several products are in development
phase, most of which have completed phase I and II
clinical trials (Figure 3 and Figure 4).
Answerabilty - is the science behind the research viable?
The first RSV vaccine (a formalin inactivated whole
virus preparation) developed over 40 years ago was asso-
ciated with increased disease severity in the vaccine reci-
pients compared to RSV infected controls [19]. Since
then although there have been numerous reports (espe-
cially over the past two decades) of an effective vaccine
being “just round the corner”, such a vaccine has been
as elusive as ever.
Active immunization
The challenge currently facing live RSV vaccine develo-
pers is the appropriate balance between attenuation and
immunogenicity [20]. This isak e yc h a l l e n g et oo v e r -
come for RSV particularly as the virus primarily affects
infants in the first 6 months of life [1]. The immune sys-
tem at this age is immature and infants have a dimin-
ished B-cell response to infection which is an obstacle
to achieving high titres of antibody [21]. Young infants
also exhibit low T helper cells and inefficient antigen
presentation. The poor response is accentuated by the
effect of maternal antibodies, which have shown to sup-
press build-up of high serum neutralising antibody in
response to immunization [22]. Live RSV vaccine shed-
ding is not influenced by maternal antibody but is much
greater in the naive child than in adults and older chil-
dren with prior infection – a strong argument that there
is substantial immunity to RSV. Thus there is only a
narrow window between sufficient attenuation and
effective immunogenicity.
Though there are shared epitopes, a potential vaccine
may need to target two subtypes (A and B) further com-
plicating the development process [23]. RSV has two
proteins – Fa n dG– which trigger the antibody
response. Protein F and the central core of protein G
remain constant in both strains and thus are major tar-
gets for subunit vaccines. G protein variability leads to
the two antigenically distinguishable strains.
There is currently optimism regarding using reverse
genetics technology to produce attenuated, genetically
engineered live vaccines as a potential solution to sev-
eral challenges faced in RSV vaccine development. The
technique allows site directed mutations or gene dele-
tions into the viral genome [24]. Several mutations can
be introduced into the genome by this process to create
a combination that achieves optimal levels of attenua-
tion and immunogenicity. Current live vaccines under
trial use gene deletion of protein NS2, which is known
to prevent initiation of an innate immune response to
viral infections [25]. Alternatively, chimeric vaccines can
be created with a backbone of an attenuated virus other
than RSV expressing immunogenic RSV proteins. This
deletion has produced vaccines that appear to be suffi-
ciently attenuated in infantsa n da r et h u sap r o m i s i n g
route [26].
Finding a suitable animal model for preclinical trials
has been difficult due to host range restriction of RSV
and the difficulty in mimicking the young age of the tar-
get population [21]. Most animal models are more resis-
tant to the virus than young infants; thus the vaccine
appears to be safer than it may be in the target popula-
tion. The pace of development of novel vaccines is lim-
ited by the need for progressive clinical trials in adults
and then in sero-positive children before it is deemed
safe for trials in sero-negative infants. There is also a
l a c ko faf u l lu n d e r s t a n d i n go ft h er o l ep l a y e db yt h e
host immune system in the pathogenesis of natural RSV
disease and in prediction of adverse reactions to vacci-
nations [21,27]. These challenges have prevented devel-
opment of a vaccine for active immunization against
RSV in infants below the age of 6 months. Nevertheless,
there are currently several candidates at various stages
of clinical trials and scientists are now hopeful of
achieving in the near future a vaccine that is sufficiently
attenuated and yet immunogenic and protective in
young infants. The panel of experts expressed moderate
levels of optimism (score around 60%) concerning the
Table 1 Details of eligibility criteria used for screening
the studies
Inclusion criteria Exclusion Criteria
- Included research into RSV
vaccine, or other vaccine that
may bear resemblance to future
RSV vaccination programs
- RSV vaccine candidate was not a
focus of the paper
- Vaccine research was targeted
at children under 5 years
- Bovine RSV vaccine or vaccine for
the elderly
- Gave an indication of
answerability, efficacy,
effectiveness, delivery, disease
burden reduction or impact on
equity of a vaccine
- Papers not directly relating to
vaccine development and its
impact
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to satisfy the criterion of answerability (Figure 5).
Maternal immunization
Maternal immunization aims to vaccinate women during
late pregnancy in order to provide increased passive
immunity to infants by antibodies transferred from pla-
centa and breast feeding. Antibodies are transferred
from mother to foetus by active transport after 32
weeks gestation [28]. It has been shown that high levels
of maternal antibody protect babies from severe RSV
related disease and hospitalisation in the first year of life
[29,30]. This is particularly promising as a successful
candidate maternal vaccine would protect infants aged
less than 6 months who form the bulk of the disease
burden and for whom it is proving to be difficult to
develop active immunization. Only one candidate of a
purified fusion protein (PFP) subunit vaccine has thus
far entered clinical trials [31,32]. This approach is
strengthened by the ability of higher titre monoclonal
antibodies to protect infants when given prophylactically
in the post-partum period. Glezen and colleagues have
demonstrated that the protection against RSV infection
Figure 2 A summary of Stage II of the CHNRI process of evaluation of an emerging intervention (an expert opinion exercise using the
CHNRI criteria). CHNRI- Child Health and Nutrition Research Initiative.
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Page 5 of 16in early infancy is correlated with maternal antibody
[33]. Active transport of maternal antibodies only occurs
during the last trimester and may not be effective in
case of premature babies (at particular risk of serious
RSV related illness). Further trials using PFP subunit
vaccines has since been discontinued since there are
concerns about the safety of subunit RSV vaccines [34].
Presented with this evidence, the panel of experts
expressed a low level of optimism (score around 40%)
concerning the ability of vaccines for maternal immuni-
zation against RSV to satisfy the criterion of answerabil-
ity (Figure 6).
Passive immunization
Current vaccines for passive immunization against RSV
deliver protection against active disease to infants at
high risk during the peak RSV season. These
Figure 3 The current status of the research into RSV vaccines for active immunization. RSV- respiratory syncytial virus.
Figure 4 The current status of the research into immunotherapy against RSV. RSV- respiratory syncytial virus.
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Page 6 of 16interventions raise serum neutralizing antibody. There
have been two products in the market; RSV immune
globulin (RespiGam; MedImmune Inc., Gaithersburg,
MD) containing high-titre human polyclonal RSV anti-
bodies [35] and Palivizumab (Synagis; MedImmune Inc.)
a humanized murine monoclonal antibody against RSV
[36]. The more recent Palivizumab is now widely used
as it has fewer adverse effects. In countries where Palivi-
zumab is currently used; it is largely only approved for
the prevention of severe RSV disease in premature
infants, those with bronchopulmonary dysplasia or hae-
modynamically unstable chronic heart failure. A more
Anti-RSV vaccine for use in infants
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Figure 5 The results of Stage II of the CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in
vaccines for active immunization of infants against RSV. CHNRI- Child Health and Nutrition Research Initiative.
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Page 7 of 16potent derivative of Palivizumab – Motavizumab –has
been evaluated and shows increasing efficacy against
medically attended LRI but was non inferior for RSV
hospitalization [37]. It is now awaiting US FDA approval
[38]. Based on these evidence, the panel of experts
expressed moderate to high levels of optimism (score
around 70%) regarding the ability of monoclonal antibo-
dies to satisfy the criterion of answerability (Figure 7).
Efficacy - the impact of the vaccines under ideal
conditions
Active immunization
The efficacy results of the various candidate vaccines for
active immunization against RSV are summarized in
Table 2. Immunization with RSV vaccine is unlikely to
prevent RSV infection altogether [39]. Natural infection
in an infant does not mount a robust enough immune
Anti-RSV vaccine for use in pregnant women
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Page 8 of 16response to prevent subsequent infection. A study in
Texas shows that 83% of those infected in the first year
of life were again infected in the second and 46% in
their third year, showing that risk of infection only
reduces after the second infection and second year [40].
It is thus hypothesised that a new candidate is likely to
need multiple doses at frequent intervals to achieve ade-
quate immunity against RSV infection [41], making it
difficult to have a successful immunization programme
in low-income countries. Thus any vaccine against RSV
Monoclonal antibodies for passive immunization against 
RSV
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Figure 7 The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in
monoclonal antibodies for passive immunization of infants against RSV. CHNRI- Child Health and Nutrition Research Initiative.
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Page 9 of 16which would eventually be licensed may only be able to
provide protection against severe ALRI, hospitalisation
and death which account for the greatest disease bur-
den. It is also likely that these vaccines could prevent
sequelae and bacterial super-infection as a result of RSV
infection.
All of the live vaccines are being designed for intrana-
sal delivery using the model of the cold-adapted influ-
enza vaccine, Flumist
®. It is hoped that this will increase
i t se f f i c a c yb ye n h a n c i n gm u c o s a li m m u n i t ya st h i si s
believed to play an important role in RSV infection.
Despite several trials of subunit vaccines, none have
been conducted on young sero-negative children. Such
trials are unlikely to be seen in the near future mainly
because of our incomplete understanding of the events
leading to the enhanced disease seen with the Formalin-
inactivated vaccine [34] and the fact that development
of PFP, (the most promising candidate), and other subu-
nit vaccines have been discontinued due to almost uni-
formly low immunogenecity.
A recombinant attenuated para-influenza type-3 can-
didate incorporating RSV protein F has also been cre-
ated using reverse genetics technology and aims to
protect against both viruses [42,43]. A candidate vac-
cine was recently shown to be safe in seropositive chil-
dren though with inadequate immunogenicity [44].
There are a host of other candidates using other
viruses as vectors such as adenovirus, Sendai virus,
Newcastle disease virus, vaccinia virus and Venezuelan
equine encephalitis virus which are beyond the scope
of this paper [45-53]. Presented with these evidence,
the panel of experts expressed moderate levels of opti-
mism (score around 60%) regarding the ability of
vaccines for active immunization against RSV to satisfy
this criterion (Figure 5).
Maternal immunization
The subunit vaccine using Purified Fusion Protein-2 was
not immunogenic enough in mothers and only low anti-
body titres were achieved thus necessitating the need for
a more potent candidate vaccine [31]. Furthermore,
research into PFP candidates has since been discontin-
ued. The panel of experts however expressed moderate
levels of optimism (score around 60 percent) regarding
efficacy of the vaccine in case one such were to be
developed (Figure 6).
Passive immunization
Passive immunization against RSV with monoclonal
antibodies is highly efficacious. The results of the recent
trials using monoclonal antibodies are summarized in
Table 3. Here too the experts expressed moderate levels
of optimism (score around 60%) regarding efficacy of
this intervention (Figure 7).
Effectiveness- maximum burden reduction potential
Nair and colleagues estimated that in the year 2005, 33.8
million new episodes of RSV-associated ALRI occurred
globally in children aged less than 5 years, of which 3.4
million were severe enough to result in hospitalisation
[1]. Ninety six percent of these episodes were in devel-
oping countries. They also estimated that in the year
2005, roughly 53,000 to 199,000 children younger than
5 years of age died from RSV associated ALRI, with 99%
of these deaths occurring in developing countries.
Developing an effective vaccine for active immuniza-
tion against RSV would result in a significant reduction
of disease burden from RSV infections. However, at
Table 2 Efficacy results of candidate vaccines for active immunization against respiratory syncytial virus
Class Vaccine structure Clinical trial phase Results
Live
attenuated
[74]
rA2cp248/404ΔNS2
rA2cp530/1009 Δ NS2
I - Not infectious in adults
- Well tolerated, no symptomatic illness
- Infected 50% and 20% sero-negative infants
respectively at a dose of 10
5 pfu
Live
attenuated
[24]
rA2cpts248/404/1030/ Δ SH I - only candidate with a demonstrated safety profile
- 44% vaccinated infants had detectable antibodies
after 2 doses of 5.3log10 pfu
b/hPIV3/
RSVF2[44]
Recombinant attenuated para-influenza virus type-3
expressing RSV-F protein
I - tested in 120 1-9 year old sero-positive children.
- acceptable safety profile
- minimally immunogenic
Subunit
[32,75,76]
Purified F Protein - PFP 1 and PFP 2 Discontinued after
phase I/ II
- Pilot study shows significant antibody titres in
children with CF
- Safe and immunogenic in 12-48 month old sero-
positive children
Subunit
[75,76]
PFP 3 Discontinued after
phase II
- Double blinded controlled multi-centre study in CF
children
- Safe and immunogenic but no reduction in LRTI
Subunit
[75,76]
BBG2Na Animal models - Safe and immunogenic in adult mice.
- Phase III trials in adult volunteers stopped due to
unexpected adverse effects
24
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maximum reduction of disease burden using the RSV
vaccines without any information on the vaccine effec-
tiveness. None of the vaccine candidates have passed
phase III trials. The potential for a RSV vaccine for herd
immunity also remains to be seen.
Though effectiveness of maternal immunization
against RSV in the general population cannot be elicited
at this stage, there are potential barriers to attaining a
high degree of effectiveness in low-income countries.
High levels of malaria in pregnant women are worrying
as this has been shown to impede active placental trans-
port in the case of maternal immunization against teta-
nus. In The Gambia, there was a 58% reduction in the
transfer of trans-placental antibody against RSV in asso-
ciation with placental malaria [54].
Several trials have been carried out to assess effective-
ness of Palivizumab across high-income countries such
as USA, Canada, France and Netherlands [55]. A study
in the USA including 2095 children showed hospitaliza-
tion rates of 2.9% in infants on Palivizumab. In a Cana-
dian study with 480 infants hospitalisation rates were
half of that quoted in the Impact-RSV study [36].
Though these studies have consistently reinforced the
safety and high effectiveness of Palivizumab, none of
these have been conducted in low and middle-income
countries. The panel was of the opinion that candidates
for all three interventions are likely to have low levels of
maximum impact on overall pneumonia disease burden
(Figures 5, 6 and 7).
Cost of development, product and implementation and
affordability
In the case of candidate vaccines for active immuniza-
tion of infants against RSV, and also the candidate vac-
cines targeting pregnant women, the experts expressed
very low levels of optimism for low product cost, afford-
ability and low cost of development. The group also
evaluated immunoprophylaxis against RSV using mono-
clonal antibodies and expressed no optimism at all
towards low product cost; very low levels of optimism
regarding affordability and low implementation cost, but
high levels of optimism regarding low development cost
(Figures 5,6,7). Clearly, cost of the product and its
implementation in developing country settings has been
the major concern of the expert panel related to all
emerging interventions against RSV.
Deliverability, sustainability and acceptability
Active immunization
Live attenuated vaccines – currently the most promising
candidates – are being developed with intranasal deliv-
ery. Along with a likely increase in effectiveness, this
would also make delivery easier due to minimal training
needs and a potential saving in total cost due to this.
Such a delivery method would obviate transmission of
blood borne infections such as Hepatitis B and HIV
associated with poor needle handling in low-income
countries. With candidates being at very early stages of
trials, there is little indication of where-if at all-it may fit
into the expanded programme on immunization (EPI)
schedule [56]. However, a potential limitation of a likely
candidate is the need for multiple doses. This may
reduce uptake depending on the number of doses and
the time interval between each, as it may not comple-
ment the current EPI schedule. Additionally, there are
no data on interactions of candidate vaccines with
others in the EPI schedule [57]. It is also hugely con-
cerning that unlike Flumist
®, all live attenuated candi-
dates thus far have required storage facilities below -70°
C which would not fit with current cold chains in most
countries and is not at all feasible in low-income coun-
tries [23]. It is hoped that this obstacle would be over-
come as the vaccine progresses through further clinical
trial stages. Finally, the safety of live RSV vaccines, in
relationship to development of recurrent wheezing and
asthma later on is a theoretical concern but needs to be
studied before it is widely used. The panel expressed
moderate levels of optimism (score around 60 percent)
on the criteria of deliverability, sustainability and accept-
ability to end users of these vaccines for active immuni-
zation against RSV (Figure 5). However, they expressed
high level of optimism (score over 80%) on the accept-
ability of these vaccines to the health workers.
As candidate vaccines have not yet reached phase IV
clinical trials, there are no cost estimates for these new
Table 3 Efficacy results of candidate vaccines for passive immunization against respiratory syncytial virus
Class Vaccine
structure
Clinical trial
phase
Results
Human polyclonal [77,78] RSV IVIG Passed clinical
trials
- 40.7% relative reduction in hospitalization compared to placebo
- 63.4% relative reduction in hospitalization compared to placebo
Humanized monoclonal Ig
[36]
Palivizumab Passed clinical
trials
- 54.7% relative reduction in hospitalisation compared to placebo
Humanized monoclonal Ig
[37]
Motavizumab III - 50% relative reduction in medically attended LRI compared to
Palivizumab.
- 26% relative reduction in hospitalisation compared to Palivizumab.
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prices are likely to be high especially with a high
demand for the vaccine in high-income countries. A
way of making an emerging intervention more deliver-
able in low and middle-income countries could be with
differential pricing of the product [58]. This works by
licensing a vaccine with the agreement of setting lower
and more affordable prices in low and middle-income
countries. The model has potential to work well in the
case of RSV as there is a great demand for a RSV vac-
cine in the developed countries, which would thus be
able to heavily subsidise the cost in the developing
countries. Since majority of the disease burden due to
RSV and influenza occur in very young children (in the
first two years of life), and both diseases have strong
seasonal pattern of transmission and the lower respira-
tory infection associated with both are known to pro-
gress rapidly, extrapolation of cost effectiveness using
analyses for an influenza vaccine may be useful. Salo
and colleagues demonstrated that investing 1.1 million
Euros on vaccinating children with an influenza vaccine
between 6 months and 3 years, reduced medical costs
by 2.8 million Euros, thereby resulting in a cost-saving
1.7 million Euros [59]. This is particularly promising as
incidence rates were underestimated and showed poten-
tial savings with a vaccine efficacy as low as 60%. Since
the burden of disease with RSV is higher than that from
influenza one could expect greater savings [60]. Addi-
tionally, benefits of potential herd immunity must be
considered. However, this particular analysis was carried
out in Finland and thus cannot be generalised globally.
The experts however, expressed low levels of optimism
(score less than 60 percent) regarding the ability to
develop the vaccine at a low cost (Figure 5).
Maternal immunization
Health care utilization indicators suggest that an effec-
tive delivery system is in place for maternal immuniza-
tion in many middle and low-income countries. Even in
countries with low hospital delivery levels, a majority of
women still attend antenatal care at least once. Green-
wood points out that more than 50% of women in 24 of
28 African countries surveyed were found to attend
antenatal clinics on four or more occasions [61]. In
addition, in many malaria endemic countries, greater
attendance is being encouraged through prevention pro-
grams in order to deliver prophylactic treatment. The
high coverage achieved by maternal immunization pro-
grams against tetanus is also particularly encouraging as
neonatal tetanus is a particular problem of extremely
poor communities [62]. However, since vaccines for
maternal immunization are still in early stages of devel-
opment, there is as yet no indication of storage require-
ments for these vaccines. The experts expressed
moderate levels of optimism (score around 60 percent)
on the criteria of deliverability and sustainability of
these vaccines (Figure 6). They however were more opti-
mistic (score around 80 percent) on the acceptability of
these vaccines to the end users and health workers. The
panel expressed concern (score around 50 percent)
about the ability to develop these vaccines at a low cost.
Passive immunization
Delivery of Palivizumab requires monthly injections for
five months through the RSV season; this may prove diffi-
cult in low-income countries for several reasons. In the
tropical and sub-tropical regions the seasonality of RSV is
not very clear as in temperate regions [63,64]. Unlike in
the US, the administration of Palivizumab in developing
countries would most likely rely on the availability of hos-
pital services which would make delivery difficult in
resource poor settings which constitute the bulk of the
disease burden. Administration of Palivizumab is only
recommended in high-risk patients. Since this decision is
based on clinical judgement, it is likely to be a limiting fac-
tor in low and middle-income countries where there is
shortfall in health manpower. Palivizumab needs to be
stored at 2 to 8° C which makes it suitable for utilizing
existing cold chain facilities available under EPI [65].
Immunoprophylaxis with Palivizumab has primarily been
in developed countries due to the high cost associated
with it. Most economic analyses show that Palivizumab
use is not cost-effective though some studies show greater
cost-efficacy specifically for use in premature infants [66].
Economic analyses for the use of Palivizumab in Argentina
demonstrated a cost of $15 358 per avoided hospitalization
while the same was at a cost of $34 840 in an Aborigine
community [67,68]. Studies in Malaysia show that a signif-
icantly better outcome was achieved for patients with RSV
bronchiolitis in hospitals where better intensive care
expertise and resource was available [69]. Many critics
have argued that in countries where health resources are
scarce, money may be better channelled into improving
intensive care units than investing in an expensive new
intervention. Since monoclonal antibodies have already
been developed, the experts were highly optimistic (score
around 90 percent) that they could be made available to
low and middle income countries at a low cost (Figure 7).
However, they were not optimistic (score around 20 per-
cent) regarding the deliverability and sustainability of
these interventions. They were however moderately opti-
mistic (score around 60 percent) regarding the acceptabil-
ity of these products to the end users and health workers.
Impact on equity
Though RSV affects young children across the world, 96
percent of the episodes occur in developing countries
[1]. Thus an equitable coverage program needs to reach
a vast proportion of the global poor. Evaluation of cur-
rent immunization and treatment programs show that
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rich populations between and within countries. This is
called inverse equity as the global poor are exposed to
higher degrees of disease, yet effective interventions fail
to reach them [70]. In many countries where several
interventions are being promoted simultaneously
(instead of encouraging universal coverage), these pro-
vide cumulative benefit to the rich and increase health
inequalities. An evaluation of coverage of several inter-
ventions in 54 priority countries showed an average cov-
erage of over 50% with less than 30% coverage in the
poorest communities [71].
This disparity is less apparent in immunization pro-
grams than with some other interventions. Yet, in 50
low and middle-income countries average coverage for
full immunization was 62% in the richest 20% and a
mere 38% in the poorest 20% [72]. These evaluations
highlight a large and growing equity gap which is preci-
pitated by the addition of new interventions. While
these interventions may be effective and succeed in
reducing disease burden, a greater proportion of deaths
could be prevented by aiming for universal coverage
with fewer interventions. Thus a new RSV vaccine is
only likely to be equitable if a novel delivery system that
aims to target poor populations is adopted [73]. The
panel was moderately optimistic (score around 70 per-
cent) about the ability of the vaccines for active and
maternal immunization to have an impact on equity
(Figures 5, 6, and 7). However, they were not optimistic
(score around 40 percent) about the ability of monoclo-
nal antibodies to satisfy this criterion.
Discussion
RSV is the most common cause of ALRI in children and
an important cause of child mortality with a high disease
burden in low and middle-income countries. The litera-
ture review summarized in this paper presents evidence
required for making an informed decision on the
research priority that should be given to emerging inter-
ventions against RSV. The scores for active and passive
immunization of infants and pregnant women with inter-
ventions against the set criteria represent the collective
optimism of a panel of experts drawn from varying tech-
nical backgrounds and affiliations. Although there are
currently no vaccines to protect against the virus, signifi-
cant progress is being made for active immunization,
with live attenuated preparations looking most promis-
ing. Recent research has increased hope for a successful
vaccine for infants as young as 2 months. However, there
have been no trials in low and middle-income countries
which are essential to assess their impact in these areas
where disease burden is highest. Pharmaceutical compa-
nies would need to seriously consider undertaking future
clinical trials in developing countries without which no
progress in reducing global childhood mortality asso-
ciated with RSV can be anticipated.
In the case of candidate vaccines for active immuniza-
tion of infants against RSV, the experts expressed low
levels of optimism for cost of product, affordability and
low cost of development and implementation; moderate
levels of optimism regarding the criteria of answerability,
likelihood of efficacy, deliverability, sustainability and
acceptance to end users for the interventions; and high
levels of optimism regarding impact on equity and
acceptance to health workers. While considering the
candidate vaccines targeting pregnant women, the panel
expressed low levels of optimism for cost of product,
affordability, low cost of development and implementa-
tion, and even answerability; moderate levels of opti-
mism for likelihood of efficacy, deliverability,
sustainability and impact on equity; high levels of opti-
mism regarding acceptance to end users and health
workers. The group also evaluated immunoprophylaxis
against RSV using monoclonal antibodies and expressed
no optimism at all towards low product cost; low levels
of optimism regarding deliverability, affordability, sus-
tainability, cost of implementation and the impact on
equity; moderate levels of optimism against the criteria
of answerability, likelihood of efficacy, acceptance to
end-users and health workers; and high levels of opti-
mism regarding low development cost. As far as the
vaccines against RSV are concerned the challenge would
be to develop a low cost, immunogenic yet safe vaccine
which can be either given to infants younger than two
months of age or develop one which can be given to
pregnant women in their last trimester.
This is the first time such an exercise has been con-
ducted with the aim of predicting the future impact of
emerging vaccines. The CHNRI methodology was pri-
marily designed to evaluate existing interventions and
competing investment priorities for health research.
Although we used the CHNRI criteria, we modified it
by including systematic review of available literature and
not involving all stakeholders (e.g. end-users and health
workers). The scores reported in this paper express the
collective opinion of a panel of 20 experts. While there
is always an element of error while predicting impact of
interventions which do not exist and have no clinical
trial data to support them (especially efficacy and maxi-
mum disease burden reduction potential), we feel that
the results would be reproducible with another panel in
a different setting.
Conclusions
To summarize, while it is not only important that
investments are made in researching new vaccines,
adequate emphasis must be made and resources allo-
cated for proper distribution of the vaccine. While
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be the most promising, the search for a candidate vac-
cine which is immunogenic yet sufficiently attenuated
is not yet over. It looks unlikely that maternal immuni-
zation would provide sufficient protection to young
infants. And while monoclonal antibodies have proven
to be effective in providing protection to high-risk
infants, high costs and need for hospitalisation for
delivery severely limit their generalisability. As more
and more countries introduce vaccines against Strepto-
coccus pneumoniae and Haemophilus influenzae type
B in their EPI, and coverage of these vaccines
increases, the burden of disease due to bacterial pneu-
monias will inevitably decrease, thus further increasing
the relative importance of viral causes. Moreover, as
most bacterial pneumonias are secondary to viral
A L R I ,i n t r o d u c t i o no fa ne f f ective vaccine against RSV
will have a compounded effect on the overall morbidity
and mortality due to childhood pneumonia.
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